The Management of Patients With Stage IIIA Non–Small Cell Lung Cancer With N2 Mediastinal Node Involvement

Restricted access

Patients with stage IIIA non–small cell lung cancer, determined based on involvement of ipsilateral mediastinal lymph nodes, represent the most challenging management problem in this disease. Patients with this stage disease may have very different degrees of lymph node involvement. The pathologic confirmation of this involvement is a key step in the therapeutic decision. The difference in the degree of lymph node compromise has prognostic and treatment implications. Based on multiple considerations, patients can be treated with induction chemotherapy, chemoradiotherapy followed by surgery, or definitive chemoradiotherapy without surgery. Data derived from clinical trials have provided incomplete guidance for physicians and their patients. The best therapeutic plan is achieved through the multidisciplinary cooperation of a team specialized in lung cancer.

Correspondence: Renato G. Martins, MD, MPH, Thoracic/Head and Neck Medical Oncology, Fred Hutchinson Cancer Research Center/Seattle Cancer Care Alliance/University of Washington, 825 Eastlake Avenue East, Seattle, WA 98109. E-mail: rgmart@u.washington.edu

Dr. Borghaei has disclosed that he is a consultant, on the advisory board, or on the speakers’ bureau for Eli Lilly and Company and Genentech, Inc. Dr. Kris has disclosed that he is a consultant for Roche and Genentech, Inc. The remaining authors have disclosed that they have no financial interests, arrangements, or affiliations with the manufacturers of any products discussed in this article or their competitors.

  • 1

    Ettinger DS, Akerly W, Bepler G. NCCN Clinical Practice Guidelines in Oncology: Non–Small Cell Lung Cancer. Version 2, 2012. Available at: NCCN.org. Accessed March 13, 2012.

    • Search Google Scholar
    • Export Citation
  • 2

    Goldstraw P, Crowley J, Chansky K. The IASLC lung cancer staging project: proposals for the revision of the TNM stage groupings in the forthcoming (seventh) edition of the TNM classification of malignant tumors. J Thorac Oncol 2007;2:706714.

    • Search Google Scholar
    • Export Citation
  • 3

    Albain KS, Swann RS, Rusch VW. Radiotherapy plus chemotherapy with or without surgical resection for stage III non-small-cell lung cancer: a phase III randomized controlled trial. Lancet 2009;374:379386.

    • Search Google Scholar
    • Export Citation
  • 4

    Shah AA, Berry MF, Tzao C. Induction chemoradiotherapy is not superior to induction chemotherapy alone in patients with stage IIIA(N2) non-small cell lung cancer: a systematic review and meta-analysis [abstract]. J Thorac Oncol 2011;6(Supp 2):S15781579. Abstract 4.290.

    • Search Google Scholar
    • Export Citation
  • 5

    Andre F, Grunenwald D, Pignon JP. Survival of patients with resected N2 non-small-cell lung cancer: evidence for a subclassification and implications. J Clin Oncol 2000;18:29812989.

    • Search Google Scholar
    • Export Citation
  • 6

    Cerfolio RJ, Bryant AS. Survival of patients with unsuspected N2 (stage IIIA) nonsmall-cell lung cancer. Ann Thorac Surg 2008;86:362367.

  • 7

    Hochstenbag MMH, Twijnstra A, Hofman P. MR-imaging of the brain of neurologic asymptomatic patients with large cell or adenocarcinoma of the lung. Does it influence prognosis and treatement? Lung Cancer 2003;42:189193.

    • Search Google Scholar
    • Export Citation
  • 8

    Hwangbo B, Kim SK, Lee HS. Application of endobronchial ultrasound-guided transbronchial needle aspiration following integrated PET/CT in mediastinal staging of potentially operable non-small cell lung cancer. Chest 2009;135:12801287.

    • Search Google Scholar
    • Export Citation
  • 9

    Darling GE, Maziak DE, Inculet RI. Positron emission tomography-computed tomography compared with invasive mediastinal staging in non-small cell lung cancer: results of mediastinal staging in the early lung positron emission tomography trial. J Thorac Oncol 2011;6:13671372.

    • Search Google Scholar
    • Export Citation
  • 10

    Farjah F, Flum DR, Varguese TK Jr. Surgeon specialty and long-term survival after pulmonary resection for lung cancer. Ann Thorac Surg 2008;87:9951004.

    • Search Google Scholar
    • Export Citation
  • 11

    Burkes RL, Ginsberg RJ, Shepherd FA. Induction chemotherapy with mitomycin, vindesine, and cisplatin for stage III unresectable non-small-cell lung cancer: results of the Toronto phase II trial. J Clin Oncol 1992;10:580586.

    • Search Google Scholar
    • Export Citation
  • 12

    Martini N, Kris MG, Flehinger BJ. Preoperative chemotherapy for stage IIIa (N2) lung cancer: the Sloan-Kettering experience with 136 patients. Ann Thorac Surg 1993;55:13651373; discussion 1373–1374.

    • Search Google Scholar
    • Export Citation
  • 13

    Elias AD, Skarin AT, Leong T. Neoadjuvant therapy for surgically staged IIIA N2 non-small cell lung cancer (NSCLC). Lung Cancer 1997;17:147161.

    • Search Google Scholar
    • Export Citation
  • 14

    Pujol JL, Rossi JF, Le Chevalier T. Pilot study of neoadjuvant ifosfamide, cisplatin, and etoposide in locally advanced non-small cell lung cancer. Eur J Cancer 1990;26:798801.

    • Search Google Scholar
    • Export Citation
  • 15

    Darwish S, Minotti V, Crino L. Neoadjuvant cisplatin and etoposide for stage IIIA (clinical N2) non-small cell lung cancer. Am J Clin Oncol 1994;17:6467.

    • Search Google Scholar
    • Export Citation
  • 16

    Kris MG, Pisters KM, Ginsberg RJ. Effectiveness and toxicity of preoperative therapy in stage IIIA non-small cell lung cancer including the Memorial Sloan-Kettering experience with induction MVP in patients with bulky mediastinal lymph node metastases (clinical N2). Lung Cancer 1995;12(Suppl 1):S4757.

    • Search Google Scholar
    • Export Citation
  • 17

    Betticher DC, Hsu Schmitz SF, Totsch M. Mediastinal lymph node clearance after docetaxel-cisplatin neoadjuvant chemotherapy is prognostic of survival in patients with stage IIIA pN2 non-small-cell lung cancer: a multicenter phase II trial. J Clin Oncol 2003;21:17521759.

    • Search Google Scholar
    • Export Citation
  • 18

    Martini N, Kris MG, Gralla RJ. The effects of preoperative chemotherapy on the resectability of non-small cell lung carcinoma with mediastinal lymph node metastases (N2 M0). Ann Thorac Surg 1988;45:370379.

    • Search Google Scholar
    • Export Citation
  • 19

    Sugarbaker DJ, Herndon J, Kohman LJ. Results of cancer and leukemia group B protocol 8935. A multiinstitutional phase II trimodality trial for stage IIIA (N2) non-small-cell lung cancer. Cancer and Leukemia Group B Thoracic Surgery Group. J Thorac Cardiovasc Surg 1995;109:473483; discussion 483–485.

    • Search Google Scholar
    • Export Citation
  • 20

    Burkes RL, Shepherd FA, Blackstein ME. Induction chemotherapy with mitomycin, vindesine, and cisplatin for stage IIIA (T1-3, N2) unresectable non-small-cell lung cancer: final results of the Toronto phase II trial. Lung Cancer 2005;47:103109.

    • Search Google Scholar
    • Export Citation
  • 21

    Garrido P, Gonzalez-Larriba JL, Insa A. Long-term survival associated with complete resection after induction chemotherapy in stage IIIA (N2) and IIIB (T4N0-1) non small-cell lung cancer patients: the Spanish Lung Cancer Group Trial 9901. J Clin Oncol 2007;25:47364742.

    • Search Google Scholar
    • Export Citation
  • 22

    Weiden PL, Piantadosi S. Preoperative chemotherapy (cisplatin and fluorouracil) and radiation therapy in stage III non-small cell lung cancer. A phase 2 study of the LCSG. Chest 1994;106(6 Suppl):344S347S.

    • Search Google Scholar
    • Export Citation
  • 23

    Taylor SG IV, Trybula M, Bonomi PD. Simultaneous cisplatin fluorouracil infusion and radiation followed by surgical resection in regionally localized stage III, non-small cell lung cancer. Ann Thorac Surg 1987;43:8791.

    • Search Google Scholar
    • Export Citation
  • 24

    D’Angelillo RM, Trodella L, Ciresa M. Multimodality treatment of stage III non-small cell lung cancer: analysis of a phase II trial using preoperative cisplatin and gemcitabine with concurrent radiotherapy. J Thorac Oncol 2009;4:15171523.

    • Search Google Scholar
    • Export Citation
  • 25

    Palazzi M, Cataldo I, Gramaglia A. Preoperative concomitant cisplatin/VP16 and radiotherapy in stage III non-small cell lung cancer. Int J Radiat Oncol Biol Phys 1993;27:621625.

    • Search Google Scholar
    • Export Citation
  • 26

    Choi NC, Carey RW, Daly W. Potential impact on survival of improved tumor downstaging and resection rate by preoperative twice-daily radiation and concurrent chemotherapy in stage IIIA non-small-cell lung cancer. J Clin Oncol 1997;15:712722.

    • Search Google Scholar
    • Export Citation
  • 27

    Favaretto A, Paccagnella A, Tomio L. Pre-operative chemoradiotherapy in non-small cell lung cancer stage III patients. Feasibility, toxicity and long-term results of a phase II study. Eur J Cancer 1996;32A:20642069.

    • Search Google Scholar
    • Export Citation
  • 28

    Eberhardt W, Wilke H, Stamatis G. Preoperative chemotherapy followed by concurrent chemoradiation therapy based on hyperfractionated accelerated radiotherapy and definitive surgery in locally advanced non-small-cell lung cancer: mature results of a phase II trial. J Clin Oncol 1998;16:622634.

    • Search Google Scholar
    • Export Citation
  • 29

    Strauss GM, Herndon JE, Sherman DD. Neoadjuvant chemotherapy and radiotherapy followed by surgery in stage IIIA non-small-cell carcinoma of the lung: report of a Cancer and Leukemia Group B phase II study. J Clin Oncol 1992;10:12371244.

    • Search Google Scholar
    • Export Citation
  • 30

    Eagan RT, Ruud C, Lee RE. Pilot study of induction therapy with cyclophosphamide, doxorubicin, and cisplatin (CAP) and chest irradiation prior to thoracotomy in initially inoperable stage III M0 non-small cell lung cancer. Cancer Treat Rep 1987;71:895900.

    • Search Google Scholar
    • Export Citation
  • 31

    Faber LP, Kittle CF, Warren WH. Preoperative chemotherapy and irradiation for stage III non-small cell lung cancer. Ann Thorac Surg 1989;47:669675; discussion 676–677.

    • Search Google Scholar
    • Export Citation
  • 32

    Recine D, Rowland K, Reddy S. Combined modality therapy for locally advanced non-small cell lung carcinoma. Cancer 1990;66:22702278.

  • 33

    Thomas M, Rübe C, Hoffnecht P. Effect of preoperative chemoradiation in addition to preoperative chemotherapy: a randomised trial in stage III non-small cell lung cancer. Lancet Oncol 2008;9:636648.

    • Search Google Scholar
    • Export Citation
  • 34

    Preoperative chemotherapy versus concurrent chemoradiotherapy in N2 positive IIIa non small cell lung cancer (NSCLC). ClinicalTrials.govidentifier: NCT00452803. Available at: www.clinicaltrials.gov/NCT00452803. Accessed November 21, 2011.

    • Search Google Scholar
    • Export Citation
  • 35

    Chemotherapy with or without radiation therapy before surgery in treating patients with stage IIIA non-small cell lung cancer. ClinicalTrials.govidentifier: NCT00030771. Available at: www.clinicaltrials.gov/NCT00030771. Accessed November 21, 2011.

    • Search Google Scholar
    • Export Citation
  • 36

    van Meerbeeck JP, Kramer GW, Van Schil PE. Randomized controlled trial of resection versus radiotherapy after induction chemotherapy in stage IIIA-N2 non-small-cell lung cancer. J Natl Cancer Inst 2007;99:442450.

    • Search Google Scholar
    • Export Citation
  • 37

    Mac Manus MP, Hicks RJ, Matthew JP., High rate of detection of unsuspected distant metastases by PET in apparent stage III non-small-cell lung cancer: implications for radical radiation therapy. Intl J Radiat Oncol Biol Phys 2001;50:287293.

    • Search Google Scholar
    • Export Citation
  • 38

    Fischer B, Lassen U, Mortensen J. Preoperative staging of lung cancer with combined PET-CT. N Engl J Med 2009;361:3239.

  • 39

    Farray D, Mirkovic N, Albain KS. Multimodality therapy for stage III non-small cell lung cancer. J Clin Oncol 2005;23:7763.

  • 40

    Aupérin A, Le Péchoux C, Rolland E. Meta-analysis of concomitant versus sequential radiochemotherapy in locally advanced non-small-cell lung cancer. J Clin Oncol 2010;28:21812190.

    • Search Google Scholar
    • Export Citation
  • 41

    Cerfolio R, Bryant A, Ojha B. Restaging patients with N2 (stage IIIA) nonsmall cell lung cancer after neoadjuvant chemoradiotherapy: a prospective study. J Thorac Cardiovasc Surg 2006;131:12291235.

    • Search Google Scholar
    • Export Citation
  • 42

    Bauwens O, Dusart M, Pierard P. Endobronchial ultrasound and value of PET for prediction of pathological results of mediastinal hot spots in lung cancer patients. Lung Cancer 2008;61:356361.

    • Search Google Scholar
    • Export Citation
  • 43

    Plat G, Pierard P, Haller A. Endobronchial ultrasound and positron emission tomography positive mediastinal lymph nodes. Eur Respir J 2006;27:276281.

    • Search Google Scholar
    • Export Citation
  • 44

    Krupitskaya Y, Loo BW Jr. Post-operative radiation therapy (PORT) in completely resected non-small-cell lung cancer. Curr Treat Opt Oncol 2008;9:343356.

    • Search Google Scholar
    • Export Citation
  • 45

    Watanabe Y, Shimizu J, Tsubota M. Mediastinal spread of metastatic lymph nodes in bronchogenic carcinoma. Mediastinal nodal metastases in lung cancer. Chest 1990;97:10591065.

    • Search Google Scholar
    • Export Citation
  • 46

    Kotoulas CS, Foroulis CN, Kostikas K. Involvement of lymphatic metastatic spread in non-small cell lung cancer accordingly to the primary cancer location. Lung Cancer 2004;44:183191.

    • Search Google Scholar
    • Export Citation
  • 47

    Cerfolio RJ, Bryant AS. Distribution and likelihood of lymph node metastasis based on the lobar location of nonsmall-cell lung cancer. Ann Thorac Surg 2006;81:19691973.

    • Search Google Scholar
    • Export Citation
  • 48

    Kelsey CR, Light KL, Marks LB. Patterns of failure after resection of non-small-cell lung cancer: implications for postoperative radiation therapy volumes. Int J Radiat Oncol Biol Phys 2006;65:10971105.

    • Search Google Scholar
    • Export Citation
  • 49

    Fowler WC, Langer CJ, Curran WJ. Postoperative complications after combined neoadjuvant treatment of lung cancer. Ann Thorac Surg 1993;55:986989.

    • Search Google Scholar
    • Export Citation
  • 50

    Sonett JR, Suntharalingam M, Edelman MJ. Pulmonary resection after curative intent radiotherapy (>59 Gy) and concurrent chemotherapy in non-small-cell lung cancer. Ann Thorac Surg 2004;78:12001205.

    • Search Google Scholar
    • Export Citation
  • 51

    Cerfolio RJ, Bryant AS, Jones VL. Pulmonary resection after concurrent chemotherapy and high dose (60Gy) radiation for non-small cell lung cancer is safe and may provide increased survival. Eur J Cardiothorac Surg 2009;35:718723.

    • Search Google Scholar
    • Export Citation
  • 52

    Edelman MJ, Paulus R, Suntharalingam M. RTOG 0229: a phase II trial of concurrent chemotherapy and full dose radiotherapy followed by surgical resection and consolidative therapy for locally advanced non-small cell carcinoma of the lung [abstract]. J Thorac Oncol 2011;6:S375376. Abstract O23.02.

    • Search Google Scholar
    • Export Citation
  • 53

    Spoelstra FOB, Senan S, Le Péchoux C. Variations in target volume definition for postoperative radiotherapy in stage III non-small-cell lung cancer: analysis of an international contouring study. Int J Radiat Oncol Biol Phys 2010;76:11061113.

    • Search Google Scholar
    • Export Citation
  • 54

    Betticher DC, Hsu Schmitz SF, Tötsch M. Prognostic factors affecting long-term outcomes in patients with resected stage IIIA pN2 non-small-cell lung cancer: 5-year follow-up of a phase II study. Br J Cancer 2006;94:10991106.

    • Search Google Scholar
    • Export Citation
  • 55

    Stefani A, Alifano M, Bobbio A. Which patients should be operated on after induction chemotherapy for N2 non-small cell lung cancer? Analysis of a 7-year experience in 175 patients. J Thorac Cardiovasc Surg 2010;140:356363.

    • Search Google Scholar
    • Export Citation
  • 56

    Kim AW, Liptay MJ, Bonomi P. Neoadjuvant chemoradiation for clinically advanced non-small cell lung cancer: an analysis of 233 patients. Ann Thorac Surg 2011;92:233241; discussion 241–243.

    • Search Google Scholar
    • Export Citation
  • 57

    Lee HY, Lee HJ, Kim YT. Value of combined interpretation of computed tomography response and positron emission tomography response for prediction of prognosis after neoadjuvant chemotherapy in non-small cell lung cancer. J Thorac Oncol 2010;5:497503.

    • Search Google Scholar
    • Export Citation
  • 58

    Mac Manus M, Hicks RJ. The use of positron emission tomography (PET) in the staging/evaluation, treatment, and follow-up of patients with lung cancer: a critical review. Int J Radiat Oncol Biol Phys 2008;72:12981306.

    • Search Google Scholar
    • Export Citation
  • 59

    Dimitrakopoulou-Strauss A, Hoffman M, Bergner R. Prediction of short-term survival in patients with advanced nonsmall cell lung cancer following chemotherapy based on 2-deoxy-2-[F-18]fluoro-D-glucose-positron emission tomography: a feasibility study. Mol Imaging Biol 2007;9:308317.

    • Search Google Scholar
    • Export Citation
  • 60

    Kong FM, Frey KA, Quint LE. A pilot study of [18F] fluorodeoxyglucose positron emission tomography scans during and after radiation-based therapy in patients with non small-cell lung cancer. J Clin Oncol 2007;25:31163123.

    • Search Google Scholar
    • Export Citation
  • 61

    Cerfolio RJ, Bryant AS, Winokur TS. Repeat FDG-PET after neoadjuvant therapy is a predictor of pathologic response in patients with non-small cell lung cancer. Ann Thorac Surg 2004;78:19031909; discussion 1909.

    • Search Google Scholar
    • Export Citation
  • 62

    Ohtsuka T, Nomori H, Ebihara A. FDG-PET imaging for lymph node staging and pathologic tumor response after neoadjuvant treatment of non-small cell lung cancer. Ann Thorac Cardiovasc Surg 2006;12:8994.

    • Search Google Scholar
    • Export Citation
  • 63

    Eschmann SM, Friedel G, Paulsen F. 18F-FDG PET for assessment of therapy response and preoperative re-evaluation after neoadjuvant radio-chemotherapy in stage III non-small cell lung cancer. Eur J Nucl Med Mol Imaging 2007;34:463471.

    • Search Google Scholar
    • Export Citation
  • 64

    Rebollo-Aguirre AC, Ramos-Font C, Villegas Portero R. Is FDG-PET suitable for evaluating neoadjuvant therapy in non-small cell lung cancer? Evidence with systematic review of the literature. J Surg Oncol 2010;101:486494.

    • Search Google Scholar
    • Export Citation
  • 65

    Gaissert HA, Keum DY, Wright CD. Operative risk of pneumonectomy-Influence of preoperative induction therapy. J Thorac Cardiovasc Surg 2009;138:289294.

    • Search Google Scholar
    • Export Citation
  • 66

    Mansour Z, Kochetkova EA, Ducrocq E. Induction chemotherapy does not increase the operative risk of pneumonectomy. Eur J Cardiothorac Surg 2007;31:181185.

    • Search Google Scholar
    • Export Citation
  • 67

    Weder W, Collaud S, Eberhardt WEE. Pneumectomy is a valuable treatment option after neoadjuvant therapy for stage III non-small-cell lung cancer. J Thorac Cardiovasc Surg 2010;139:14241430.

    • Search Google Scholar
    • Export Citation
All Time Past Year Past 30 Days
Abstract Views 0 0 0
Full Text Views 422 291 29
PDF Downloads 164 132 10
EPUB Downloads 0 0 0